Figure 1 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Year: 2026
Type: other
Abstract: A–C, Best change from baseline in target lesion size (left panels) and DOR (right panels). Left, dotted lines indicate thresholds for partial response (−30%) and progressive disease (20%). One patient who received the oleclumab combination had a CR in their target lesion but experienced progressive disease in a nontarget lesion, with an overall response of progressive disease. *, If the best percentage change from baseline of target lesions was not calculated because of progression, withdrawal, or death, the value was imputed at +20%; , patients with progressive disease as best overall response; #, unconfirmed response. Right, each bar represents an individual patient. Partial response and CR to treatment as well as disease progression are shown as symbols within the colored bars; stable disease is not represented. The length of each bar indicates the duration of treatment. PD-L1 expression was assessed with the VENTANA PD-L1 (SP263) Assay (Roche Diagnostics). Expression was defined as the percentage of the tumor area populated by tumor cells with membranous staining for PD-L1 or immune cells with membranous, cytoplasmic, or punctate PD-L1 staining at any intensity (TAP score). A TAP score ≥10% was considered positive, whereas a TAP score <10% was considered negative. N, no; U, unknown; Y, yes.
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7203481818
Cites:
Cited by:
Related to: